HTTIF (HighTide Therapeutics) Other Stockholders Equity: $29.39 Mil (As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.39
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics Other Stockholders Equity?

HighTide Therapeutics HTTIF 14 Other Stockholders Equity is $29.39 Mil as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

HighTide Therapeutics's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $29.39 Mil.

HighTide Therapeutics's quarterly Other Stockholders Equity increased from Dec. 2024 ($25.60 Mil) to Jun. 2025 ($27.58 Mil) and increased from Jun. 2025 ($27.58 Mil) to Dec. 2025 ($29.39 Mil).

HighTide Therapeutics's annual Other Stockholders Equity increased from Dec. 2023 ($11.65 Mil) to Dec. 2024 ($25.60 Mil) and increased from Dec. 2024 ($25.60 Mil) to Dec. 2025 ($29.39 Mil).

HighTide Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics Other Stockholders Equity Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
-0.00 0.45 11.65 25.60 29.39

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only 11.65 19.30 25.60 27.58 29.39
HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $29.39 Mil mean?
HighTide Therapeutics (HTTIF) has a Other Stockholders Equity of $29.39 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on HighTide Therapeutics and its competitors.
Is HighTide Therapeutics' Other Stockholders Equity too high?
HighTide Therapeutics' current Other Stockholders Equity is $29.39 Mil. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Other Stockholders Equity compare to VRTX and REGN?
HighTide Therapeutics' Other Stockholders Equity of $29.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on HighTide Therapeutics and its competitors. HighTide Therapeutics's current Other Stockholders Equity is $29.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Other Stockholders Equity of $29.39 Mil. The current Other Stockholders Equity is $29.39 Mil. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Other Stockholders Equity is $29.39 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price